Table 3.
GLP-2-based therapeutic peptides.
| Peptide Name | AA Sequence | Development Stage | Reference |
|---|---|---|---|
| Native GLP-2(1-33) | HADGSFSDEMNTILDNLAARDFINWLIQTKITD | N/A | (205) |
| [Gly2]GLP-2 | HGDGSFSDEMNTILDNLAARDFINWLIQTKITD | Preclinical | (209, 214) |
| Teduglutide | HGDGSFSDEMNTILDNLAARDFINWLIQTKITD | Approved 2012-SBS (Shire-NPS Pharmaceuticals) | (222–223) |
| Apraglutide | HGDGSFSDE-Nle-(DF)TILDLLAARDFINWLIQTKITD | Phase III-SBS (VectivBio) | (224, 225) |
| Glepaglutide | HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK | Phase III-SBS (Zealand Pharma) | (226) |
Amino acid sequences are provided in their single-letter abbreviation format. Modifications from native sequences are highlighted by red lettering. Current development stages, and associated condition, and holding companies (in brackets) are provided (where available) for each are provided for each. A “D” prefix before a residue indicates inclusion of the enantiomer for the naturally-occurring L form of the residue. “Nle” indicates the addition of a norleucine residue.